Galderma Group AG (GDERF)
| Market Cap | 48.00B +66.0% |
| Revenue (ttm) | 4.69B +8.6% |
| Net Income | 378.00M |
| EPS | 1.59 |
| Shares Out | n/a |
| PE Ratio | 126.99 |
| Forward PE | 48.64 |
| Dividend | 0.18 (0.09%) |
| Ex-Dividend Date | Apr 25, 2025 |
| Volume | 200 |
| Average Volume | 1,089 |
| Open | 191.55 |
| Previous Close | 203.74 |
| Day's Range | 191.55 - 202.20 |
| 52-Week Range | 108.10 - 213.50 |
| Beta | n/a |
| RSI | 57.63 |
| Earnings Date | Mar 5, 2026 |
About Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes ACTINICA, Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, Mirvaso, NEMLUVIO, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology. ... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Galderma Announces Appointment of New Chief Financial Officer
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effectiv...
We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra's Regenerative Properties
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Scul...
Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT‑based hyaluronic ac...
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe ...
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin ...
Galderma Unveils ‘Wake Up To Restylane', Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane', a global campaign that showcases Restylane as an everyday beaut...
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry's Broadest Injectable Aesthetics Portfolio
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) will present ten posters with the latest updates from across its broad aesthetic portfolio spanning regenerative biostimulation, HA and neuromod...
Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirmin...
TOXINS 2026: Clinical Updates on Galderma's Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) will present data on its innovative and industry-leading neuromodulator portfolio at the TOXINS 2026 International Conference in Madrid, Spain f...
Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and s...
L'Oreal Doubles Stake in Swiss Skincare Company Galderma
Financial terms weren't disclosed., but the package of about 24 million Galderma shares would be valued at $4.85 billion based on Friday's closing price.
EQT agrees to sale of shares in Galderma Group AG to L'Oréal S.A.
C. 24 million shares to be sold STOCKHOLM , Dec. 8, 2025 /PRNewswire/ -- Further to previous announcements, an affiliate of the funds known as EQT VIII ("EQT") is pleased to announce it has signed an ...
L'Oreal increases stake in Galderma to 20%
French cosmetics group L'Oreal increased its stake in dermatology firm Galderma to 20%, as it bought a further 10% stake in the company, the Swiss firm said in a statement on Monday.
L'ORÉAL GROUPE TO REINFORCE ITS STRATEGIC INVESTMENT IN GALDERMA WITH AN ADDITIONAL 10% BRINGING ITS TOTAL PARTICIPATION TO 20%
L'ORÉAL GROUPE TO REINFORCE ITS STRATEGIC INVESTMENT IN GALDERMA WITH AN ADDITIONAL 10% BRINGING ITS TOTAL PARTICIPATION TO 20%
Galderma Welcomes Increased Equity Investment From L'Oréal
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L'Oréal Groupe intends to increase its equity investment in the company...
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) follow...
Galderma Secures ‘BBB' Credit Rating With Positive Outlook from S&P Global Ratings
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB' long-term iss...
ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma's Innovative Injectable Aesthetics Portfolio and Pipeline
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfolio and pipeline at ...
Galderma Completes Successful Placement of CHF 175 Million Bond
ZUG, Switzerland--(BUSINESS WIRE)--NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group...
Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Restyl...
EQT completes sale of shares in Galderma Group AG
STOCKHOLM, Oct. 30, 2025 /PRNewswire/ -- Further to previous announcements, an affiliate of the funds known as EQT VIII ("EQT") is pleased to announce the completion of the placement of 20 million sha...
Galderma Group AG (GALDY) Q3 2025 Sales Call Transcript
Galderma Group AG (OTCPK:GALDY) Q3 2025 Sales Call October 23, 2025 9:30 AM EDT Company Participants Emil Ivanov - Head of Strategy, Investor Relations & ESG Flemming Ornskov - CEO & Director Thomas J...
Galderma Delivers Record Net Sales of 3.737 Billion USD in the First Nine Months of 2025 and 15.0% Year-on-Year Growth at Constant Currency, Raises Full-Year Guidance
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first nine months of 2025, delivering record n...
AMWC Dubai: Galderma Demonstrates Injectable Aesthetics Leadership Through Updates on Its Scientific Innovations and Community Education
ZUG, Switzerland--(BUSINESS WIRE)--Galderma will present six posters with the latest updates from its science-backed aesthetic portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in...
Galderma's Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin
ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles and t...